Lopes-Virella MF, et al. - Researchers assessed if, in type 1 diabetes, there is a link between the composition of modified forms of LDL in circulating immune complexes (LDL-IC) and CVD results, including any CVD, major adverse cardiac and cerebrovascular events (MACCE), myocardial infarction (MI), and coronary artery disease (CAD). In most cases, baseline levels of modified LDL-IC (quantified several years before any CVD event occurred) were linked to CVD risk over a 25-year period, even following adjustment for other risk factors (including LDL-cholesterol). Modified LDL biomarkers can, therefore, help to recognize patients with type 1 diabetes also at high risk for MACCE and CVD events very early in disease development, prior to other disease signals becoming apparent.